Contemporary data on treatment practices for low-density lipoprotein cholesterol in 6794 patients with stable coronary heart disease across the world

@inproceedings{Gitt2018ContemporaryDO,
  title={Contemporary data on treatment practices for low-density lipoprotein cholesterol in 6794 patients with stable coronary heart disease across the world},
  author={Anselm Kai Gitt and Dominik Lautsch and Jean Ferri{\`e}res and Gaetano Maria De Ferrari and Ami M Vyas and Carl A. Baxter and Lori D. Bash and Veronica Ashton and Martin Horack and Wael A Almahmeed and Fu-Tien Chiang and Kian-Keong Poh and Philippe Brudi and Baishali M Ambegaonkar},
  booktitle={Data in brief},
  year={2018}
}
DYSIS II CHD was a longitudinal, observational study in 6794 patients from 18 countries. They were attending an outpatient physician appointment for coronary heart disease (CHD). 6370 patients (93.8%) were on active lipid lowering therapy (LLT). The mean atorvastatin dose equivalent was 25 mg per day and 10.5% received ezetimibe in combination with a statin… CONTINUE READING